Stock Analiz

Niagen Bioscience, Inc. NAGE

Medicinal Chemicals and Botanical Products · data as of November 13, 2026

$2.06Market cap $164M
Open the interactive analysis →

Niagen Bioscience, Inc. (NAGE) is a healthcare company listed in the US with a market value of about $164M. In the twelve months to September 30, 2026 it had revenue of $122M and net income of $10M, a net margin of 8.4%.

Its overall Stock Analiz score is 2.4 out of 5 (weak). The strongest part is future growth (4/5); the weakest is shareholder returns (1/5).

Key numbers: a P/E of 17.2, 5-year revenue growth of 17% a year, a 5-year average ROIC of -17%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 55% below the current price.

About Niagen Bioscience

Niagen Bioscience is listed in the US and classified in medicinal chemicals and botanical products. Revenue went from $15M in 2014 to $129M in 2025, growth of about 21.4% a year. It was profitable in 2 of the last 10 years in our data. Its share count rose by 23% over three years (dilution for shareholders). It spends 5% of revenue on research and development.

Score: 2.4 / 5

Value2/5
Future growth4/5
Track record2/5
Financial health3/5
Shareholder returns1/5

Checks passed

  • P/E below 25
  • P/E below the industry median
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • 5-year revenue growth above 8% a year
  • ROE above 15%

Checks not passed

  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year
  • 5-year average ROIC above 12%
  • Profitable 5 years in a row
  • Positive free cash flow

Valuation

P/E (TTM)17.2
Forward P/E—
P/FCF—
P/S1.3
P/B2.0
EV/EBITDA17.4
PEG—
Dividend yield0.00%
FCF yield—
Shareholder yield0.1%
Intrinsic value vs. price−55%

Growth and quality

Revenue growth (1 yr)29.9%
Revenue growth (5 yrs, per year)16.9%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-9.4%
ROIC (5-yr avg.)-17.2%
Profitable years (of last 10)2
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$122M$129M$100M$84M$72M$67M$59M$46M$32M$21M$22M
Net income$10M$17M$9M-$5M-$17M-$27M-$20M-$32M-$33M-$11M-$3M
Free cash flow———————-$21M-$22M-$11M-$4M
EPS (diluted)$0.12$0.20$0.11$-0.07$-0.24$-0.40$-0.33$-0.56$-0.00$-0.00$-0.00
Net margin8.4%13.4%8.6%-5.9%-23.0%-40.2%-33.6%-69.5%-105.6%-53.7%-13.5%
ROIC—19.6%15.3%-17.6%-44.8%-58.7%-87.0%-77.2%-95.9%-30.2%-29.1%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

What is Niagen Bioscience’s P/E ratio?

About 17.2, based on the last twelve months of diluted earnings per share.

Is Niagen Bioscience stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 55% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Niagen Bioscience pay a dividend?

Not currently.

Is Niagen Bioscience a good stock to buy?

We do not give buy or sell advice. Niagen Bioscience scores 2.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.